Veracyte has acquired Convergent Genomics in a transaction valued at up to $180 million, adding the UroAmp urinary tumor DNA ...

For appropriately selected patients with muscle-invasive bladder cancer, preserving the bladder can be a curative treatment ...

The recommendations were developed by a multidisciplinary task force and are based on a systematic review of literature ...

Merck & Co., Inc. MRK secured a favorable recommendation from a European regulatory committee for its cancer therapy Keytruda in combination with Padcev to treat adults facing resectable ...

Final Results From the ATALANTE/ENGOT-ov29 Randomized Phase III Trial of Atezolizumab, Bevacizumab, and Platinum-Based Therapy for Late-Relapsing Recurrent Ovarian Cancer We conducted a systematic ...

A new at-home urine test detected 92% of bladder cancers in a study, potentially offering faster, less invasive cancer detection.

NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

Merck (NYSE:MRK) received a positive opinion from the EMA’s CHMP for KEYTRUDA plus Padcev in muscle-invasive bladder cancer. The CHMP backed the combination as perioperative therapy for adults with ...

Despite falling short of analyst expectations, Tyra Biosciences is taking its cancer drug to registrational development for ...

Patients saw improved event-free survival and overall survival with presurgical Imfinzi and chemotherapy followed by surgery and postsurgical Imfinzi. Treatment with Imfinzi (durvalumab) before and ...

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...